Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (Collaborative U01)
The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to continue follow-up of the Diabetes Prevention Program Outcomes Study (DPPOS) cohort through a collaborative cooperative agreement. The Diabetes Prevention Program (DPP) was a multi-center controlled clinical trial examining the efficacy of treatments to prevent or delay the development of type 2 diabetes in a population at high risk. The DPP demonstrated that either lifestyle change or the drug metformin could reduce the development of type 2 diabetes by 58% and 31%, respectively, compared with placebo. Following the end of DPP, the DPP cohort was enrolled in the DPPOS to determine the long-term effects of the DPP interventions on further diabetes development and microvascular complications. The primary purpose of this FOA is to support the DPPOS Biostatistics Research Center to continue follow-up of the DPPOS cohort to examine the effectiveness of early metformin treatment on the development of cardiovascular disease and cancer. RFA DK-15-503 will support continuation of the DPPOS clinical sites.
Office: National Institutes of Health
FBOWebmaster@OD.NIH.GOV
